Press release
Targeted Protein Degradation Market worth $9.85 billion by 2035 with 35.4% CAGR | MarketsandMarkets Trademark

Browse 380 market data Tables and 60 Figures spread through 402 Pages and in-depth TOC on "Targeted Protein Degradation Market - Global Forecast to 2035" View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/targeted-pro
The global Targeted Protein Degradation Market [https://www.marketsandmarkets.com/Market-Reports/targeted-protein-degradation-analysis-market-219352281.html?utm_source=abnewswire.com&utm_medium=paidpr&utm_campaign=targetedproteindegradationmarket], valued at US$0.01 billion in 2024, stood at US$0.48 billion in 2025 and is projected to advance at a resilient CAGR of 35.4% from 2025 to 2035, culminating in a forecasted valuation of US$9.85 billion by the end of the period. This is mainly due to various factors such as Priority/Fast Track designations and expected first-in-class approvals & and multi-indication expansion. However, the CMC & scale-up complexity for heterobifunctional & IP disputes are predicted to cause market growth barriers.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=219352281 [https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=219352281&utm_source=abnewswire.com&utm_medium=paidpr&utm_campaign=targetedproteindegradationmarket]
Browse in-depth TOC on "Targeted Protein Degradation Market"
380 - Tables
60 - Figures
402 - Pages
By formulation, the global targeted protein degradation market is segmented by formulation into two main categories: oral and injections. In 2024, the oral formulations segment holds the highest share in the formulation landscape of the novel TPD market, driven by its favorable pharmacokinetics, patient compliance, and manufacturing scalability. Oral delivery remains the preferred route due to its non-invasive nature and ease of administration, which significantly enhances patient adherence, especially in chronic or long-term treatments. The advancements in medicinal chemistry have enabled the development of orally bioavailable degraders, overcoming early limitations of poor solubility and permeability. Many first-generation PROTACs faced challenges with oral bioavailability due to their large molecular weight and polarity; however, recent innovation in structural optimization has yielded degrader candidates suitable for oral dosing without compromising efficacy. From a commercial perspective, oral formulations offer cost-efficiency in distribution and storage, adding to their attractiveness. Oral TPD candidates in oncology, immunology, and neurology have shown promising clinical progress, reinforcing confidence in this route. As the TPD field matures, oral formulations are expected to dominate clinical pipelines and product launches, setting the standard for patient-friendly, scalable therapeutic solutions. The continued investment in optimizing oral bioavailability across heterobifunctional and molecular glue degraders is anticipated to fuel segment growth.
By Type, the PROTACs (PROteolysis TArgeting Chimeras) segment was the fastest-growing within the targeted protein degradation (TPD) market due to their ability to selectively eliminate, rather than inhibit, disease-causing proteins. By leveraging the natural ubiquitin-proteasome system of cells, PROTACs redirect E3 ligases to tag specific proteins for degradation, offering a novel approach to address previously undruggable targets. Unlike conventional inhibitors, PROTACs can achieve greater potency and sustained therapeutic effects, often requiring lower doses and showing potential to overcome resistance mechanisms. This has sparked intense interest from the pharmaceutical industry, leading to a rapidly expanding pipeline with numerous candidates advancing through preclinical and clinical development. Clinical-stage PROTACs like ARV-471, ARV-110, and NX-2127 are being evaluated in oncology, particularly in hormone-driven cancers. Ongoing innovation in linker chemistry, E3 ligase selection, and optimization for oral delivery is driving improvements in drug-like properties. With increasing investments, strategic collaborations, and a broadening scope across therapeutic areas, PROTACs are poised to become a cornerstone of next-generation drug discovery. Their versatility and ability to precisely degrade specific proteins continue to position them as a leading modality within the growing TPD market.
By geography, the market for targeted protein degradation is divided into six segments: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America holds the largest share in the targeted protein degradation (TPD) market, driven by strong R&D infrastructure, robust funding ecosystems, and a favorable regulatory environment. The region is home to several pioneering biotechnology and pharmaceutical companies that are leading the development of TPD platforms, particularly PROTACs and molecular glues. Major players such as Arvinas, C4 Therapeutics, and Nurix Therapeutics are headquartered in the US, benefiting from access to top-tier research institutions and a highly skilled scientific workforce. In addition, consistent capital inflow from venture capital firms, public markets, and strategic pharmaceutical partnerships has accelerated innovation and clinical progression of TPD candidates. The US Food and Drug Administration (FDA) has also played a critical role by granting fast track and orphan drug designations to promising TPD candidates, thereby expediting their development and regulatory pathways. Increasing investment in oncology, neurodegenerative diseases, and autoimmune indications, which are the key therapeutic areas for TPDs, will continue to drive demand in the region. Academic-industry collaborations, the presence of large-scale clinical trial networks, and a strong intellectual property framework further enhance the leadership position of North America. These combined factors position the region to achieve the highest growth trajectory in the global TPD market.
Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=219352281 [https://www.marketsandmarkets.com/requestsampleNew.asp?id=219352281&utm_source=abnewswire.com&utm_medium=paidpr&utm_campaign=targetedproteindegradationmarket]
Key players in the targeted protein degradation market include Bristol Myers Squibb (US), Arvinas (US), BeiGene (US), Nurix (US), Kymera (US), C4 Therapeutics (US), Stemline Therapeutics (US), AstraZeneca (UK), F. Hoffmann-La Roche Ltd (Switzerland), Bayer (Vividion) (Germany), Captor Therapeutics (Poland), Ranok Therapeutics (US), Pfizer (US), Novartis (Switzerland), and Foghorn Therapeutics (US).
Bristol Myers Squibb:
Bristol Myers Squibb (BMS) is a key player in the targeted protein degradation (TPD) market, leveraging its extensive drug development capabilities to advance next-generation therapeutics. BMS was among the earliest large pharmaceutical companies to recognize the potential of TPD, particularly through molecular glues that reprogram E3 ligases to degrade disease-causing proteins. The company inherited significant TPD assets and expertise by acquiring Celgene, including its partnership with Evotec and initial collaborations with startups such as C4 Therapeutics. BMS continues to build a robust pipeline of TPD candidates, especially in oncology and immunology, where traditional small molecules or biologics have limited efficacy. Its approach combines in-house discovery with strategic partnerships to broaden target scope and accelerate clinical progression. With ongoing investments in E3 ligase biology and protein degradation mechanisms, BMS is positioning itself as a long-term leader in the TPD space. Its focus on molecular glues and degrader programs highlights a commitment to expanding and offering new therapeutic avenues for complex diseases.
Arvinas:
Arvinas is a pioneer in the targeted protein degradation (TPD) field, recognized for being the first company to bring a PROTAC (PROteolysis TArgeting Chimera) degrader into clinical trials. Founded on technology from Yale University, Arvinas has developed a proprietary platform that harnesses the ubiquitin-proteasome system to selectively degrade disease-causing proteins. Its clinical pipeline includes ARV-110 and ARV-471, which target androgen and estrogen receptors in prostate and breast cancers, respectively. Its strong scientific foundation and first-mover advantage have positioned it as a leader in the TPD space. In addition to internal programs, Arvinas has formed high-profile collaborations with Pfizer and Bayer, leveraging its platform to explore new targets and therapeutic areas beyond oncology. These partnerships validate its technology and provide significant funding and development support. As the TPD field matures, Arvinas stands out for its clinical progress, strategic alliances, and expanding expertise in rational degrader design, which could lead to transformative therapies for patients with limited treatment options.
For more information, Inquire Now! [https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=219352281&utm_source=abnewswire.com&utm_medium=paidpr&utm_campaign=targetedproteindegradationmarket]
Media Contact
Company Name: MarketsandMarkets Trademark Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=targeted-protein-degradation-market-worth-985-billion-by-2035-with-354-cagr-marketsandmarkets]
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/targeted-protein-degradation-analysis-market-219352281.html
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Targeted Protein Degradation Market worth $9.85 billion by 2035 with 35.4% CAGR | MarketsandMarkets Trademark here
News-ID: 4165663 • Views: …
More Releases from ABNewswire

Burna Boy Concert Tickets on a Budget: Lowest Prices with CITY10 Discount at Cap …
Catch Burna Boy live without breaking the bank! CapitalCityTickets.com offers the lowest prices on Burna Boy concert tickets. Use promo code CITY10 for extra savings and secure your spot at his electrifying shows. Don't miss out on the Afrobeat sensation-grab affordable tickets today and experience an unforgettable night of music and energy!
Are you a Burna Boy fan itching to catch the Afrobeat king live without draining your wallet? With his…

Best Deals on Jeff Dunham Live Shows: Low Prices Using Promo Code CITY10 via Cap …
Score big savings on Jeff Dunham live shows with CapitalCityTickets.com! Fans can find the best deals on tickets to see the world-famous ventriloquist and comedian live on stage. With promo code CITY10, enjoy an extra 10% off already low-priced tickets. Don't miss your chance to catch Dunham and his hilarious cast of characters on tour while saving money. Secure your Jeff Dunham tickets today and experience a night of nonstop…

Small Business, Big Relief: CopperJoint Highlights Family Roots with New Compres …
As a small, family-run business based in the U.S., CopperJoint blends heart and science in every product. The new compression socks for women and men combine a modern look with doctor-approved compression and all-day support - ideal for healthcare workers, professionals, and active adults. "We may be small, but our impact is felt every time a customer says, 'I can move without pain again.'"
NASHVILLE, TN - September 21, 2025 -…

Kitchen Remodeling Enhances Both Functionality and Aesthetics in Homes
Modern upgrades focus on more than just visual appeal; they deliver functional improvements that make daily living easier.
Kitchen remodeling [https://neadesignandconstruction.com/#:~:text=01,Kitchen%20Remodeling] continues to shape the way homes are experienced across New Jersey, as families prioritize comfort, efficiency, and long-lasting design. Modern upgrades focus on more than just visual appeal; they deliver functional improvements that make daily living easier. With demand rising for reliable services, homeowners are turning to trusted providers like…
More Releases for TPD
Targeted Protein Degradation Market Exclusive Trends Analysis with Forecast to 2 …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Targeted Protein Degradation Market"- Distribution by Type of Degrader (SERD, PROTAC and Molecular Glue), Target Indication (Breast Cancer and Multiple Myeloma), Industry Trends, and Global Forecasts, 2024-2031 And Segment Revenue and Forecast To 2031."
The Targeted Protein Degradation Market is estimated to reach over USD 2.65 Bn by 2031, exhibiting a CAGR of 26.3% during the…
Targeted Protein Degradation Market Exclusive Report with Detailed Study Analysi …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Targeted Protein Degradation Market"- Distribution by Type of Degrader (SERD, PROTAC and Molecular Glue), Target Indication (Breast Cancer and Multiple Myeloma), Industry Trends, and Global Forecasts, 2024-2031 And Segment Revenue and Forecast To 2031."
The Targeted Protein Degradation Market is estimated to reach over USD 2.65 Bn by 2031, exhibiting a CAGR of 26.3% during the…
Targeted Protein Degradation Market : Embracing Size Expansion with 26.3% CAGR S …
Targeted Protein Degradation Market is estimated to reach over USD 2.65 Bn by 2031, exhibiting a CAGR of 26.3% during the forecast period.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " [https://www.insightaceanalytic.com/report/targeted-protein-degradation-market/2530]"- Distribution by Type of Degrader (SERD, PROTAC and Molecular Glue), Target Indication (Breast Cancer and Multiple Myeloma), Industry Trends, and Global Forecasts, 2024-2031 And Segment Revenue and Forecast To 2031."
The Targeted…
TPD Show Potential For The Treatment of Alzheimer's Disease
Targeted protein degradation (TPD) is a promising strategy in the field of drug discovery. In recent years, targeted protein degradation (TPD) technology has developed rapidly, especially proteolysis targeting chimera (PROTAC), which is the most representative technology of TPD strategy. TPD drugs are one of the hot spots of new drug development in recent years, especially in the field of oncology. For example, a TPD drug developed by Arvinas has achieved…
Targeted Protein Degradation (TPD) Market 2021 | Detailed Report
Global Targeted Protein Degradation (TPD) Market 2021-2027, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market. An exclusive data offered in this report is collected by research and industry experts team.
Get Free Sample PDF (including full TOC, Tables…
Project Analysis of DSMAC 8000 tpd Limestone Crushing Line
DSMAC has contracted on a 8000 TPD limestone crushing line project at the end of 2012. How about the feasibility of this production line? Will it become profitable in the future? There is a project analysis from DSMAC.
Project Overview:
Productivity: 8000tpd limestone crushing line
Contractor: DSMAC
Site: India
Project Feature: aggregate production and limestone production for cement plant
Application Demand: cement raw material, sandstone and aggregate, concrete production
Crushing line configuration: DPC1818 single stage hammer…